Abstract
Finding biomarkers for predicting anti-tumor responses and immune-related adverse events (irAEs) with immune checkpoint therapy remains a challenge. Lozano et al. have developed a composite biomarker score that includes the frequency of effector-memory CD4 T cells and TCR clonality of CD4 T cells in peripheral blood as a potentially predictive biomarker of irAEs.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 249-251 |
| Number of pages | 3 |
| Journal | Cancer cell |
| Volume | 40 |
| Issue number | 3 |
| DOIs |
|
| State | Published - Mar 14 2022 |
ASJC Scopus subject areas
- Oncology
- Cell Biology
- Cancer Research
Fingerprint
Dive into the research topics of 'A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS